Key result
Triptan use in migraine linked to ~7% higher stroke risk vs the general population.
Cohort
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND: Identifying migraineurs by triptan utilization we studied risk for stroke in migraineurs compared to the general population. METHODS: A cohort study including all citizens 25-80years of age in Denmark 2003-2011 was conducted. All persons prescribed triptans, and all those hospitalized for a first stroke were identified in the Danish Registries. Information on stroke severity/subtype and cardiovascular risk factors was available for stroke patients. FINDINGS: Of the 49,711 patients hospitalized for a first stroke, 1084 were migraineurs using triptans. Adjusting for age, sex, income, and educational level, risk for stroke was higher among migraineurs in respect to all strokes (RR 1.07; CI 1.01-1.14) and ischemic strokes (RR 1.07; CI 1.00-1.14). Risk for hemorrhagic stroke was increased but only in women (RR 1.41; CI 1.11-1.79). Risk was for mild strokes (RR 1.31; CI 1.16-1.48) while risk for severe strokes was lower among migraineurs (RR 0.77; CI 0.65-0.91). Risk was age-related; highest among women 25-45years (RR≈1.7). Risk was unrelated to numbers of dispensations. INTERPRETATION: Migraineurs identified by triptan utilization had higher risk for stroke. Strokes were minor and cardiovascular risk factors were less prevalent pointing to a migraine-specific etiology of stroke different from that of thromboembolism.
No takes yet. Share an insight, caveat, or question.
Albieri et al. (2016) conducted a cohort in Migraine and Stroke. Migraine with triptan utilization vs. General population without triptan utilization was evaluated on Hospitalization for a first stroke (all strokes) (RR 1.07, 95% CI 1.01-1.14). Migraineurs using triptans had a higher risk of all strokes and mild strokes compared to the general population.
Synapse has enriched 10 related papers. Consider them for comparative context: